SCHEMBL5378740

SCHEMBL5378740

CCCC(=O)Nc1cccc(-c2n[nH]c3ccc(-c4nc[nH]n4)cc23)c1.CCCC(=O)Nc1cccc(-c2nn(C3CCCCO3)c3ccc(-c4ncn(C(c5ccccc5)(c5ccccc5)c5ccccc5)n4)cc23)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 7/20 0.38
AURKA O14965 6/20 0.38
FGFR1 P11362 1/20 0.37
DDR2 Q16832 1/20 0.37
MAPK8 P45983 3/20 0.35
TTK P33981 3/20 0.35
GSK3A P49840 3/20 0.34
GSK3B P49841 3/20 0.34
MAP3K5 Q99683 2/20 0.34
CLK2 P49760 2/20 0.34
DYRK1A Q13627 2/20 0.34
CLK3 P49761 1/20 0.34
CPT2 P23786 1/20 0.33
CPT1A P50416 1/20 0.33
ROCK2 O75116 2/20 0.33
PRKD3 O94806 2/20 0.33
PRKCG P05129 2/20 0.33
CDK2 P24941 2/20 0.33
AKT1 P31749 2/20 0.33
AKT2 P31751 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5397809 0.91 PTPN1 (0.36) FGFR1DDR2CPT2CPT1AMAP4K4
SCHEMBL5378724 0.88 SMN1; SMN2 (0.39) FGFR1DDR2MAP4K4MAPK1
SCHEMBL5391965 0.86 FGFR1 (0.36) FGFR1DDR2CPT2CPT1AMAP4K4
SCHEMBL5380109 0.84 L3MBTL1 (0.39) AURKBAURKAFGFR1DDR2MAP4K4
SCHEMBL5380244 0.84 MMP2 (0.36) FGFR1DDR2TTKMAP4K4MAPK1
SCHEMBL14554188 0.84 MAP4K4 (0.36) FGFR1DDR2CPT2CPT1AMAP4K4
SCHEMBL5373247 0.84 ECE1 (0.38) FGFR1DDR2CPT2CPT1AMAP4K4
SCHEMBL5372575 0.83 MAP4K4 (0.38) FGFR1DDR2CPT2CPT1AMAP4K4
SCHEMBL5386995 0.83 MAPT (0.38) AURKBAURKAFGFR1DDR2MAPK8
SCHEMBL5383426 0.83 MAP4K4 (0.38) FGFR1DDR2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7211594-B2 Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith SIGNAL PHARMACEUTICALS, LLC (US) 2007-05-01 US disclosed
US-20040127536-A1 Methods for treating an inflammatory condition or inhibiting JNK SIGNAL PHARMACEUTICALS, LLC 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127536-A1 Methods for treating an inflammatory condition or inhibiting JNK MAPK1, MAP3K1, MAPKAPK2 AURKB 2180/4885AURKA 3307/4885FGFR1 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.